Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy
- Conditions
- Prostate NeoplasmProstate Cancer
- Interventions
- Radiation: Ultrahypofractionated MR-guided radiotherapy boost
- Registration Number
- NCT05373316
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
The AFFIRM trial tests the safety and clinical feasibility of MR-guided hypofractionated focal boost radiotherapy for patients with locally advanced prostate cancer. External beam radiotherapy combined with androgen deprivation therapy is considered as the treatment of choice for patients with locally advanced non-metastatic prostate cancer with seminal vesicle invasion.The long-term results of the multicentre phase III study (FLAME trial) showed that addition of an isotoxic focal boost to the intraprostatic lesion improves biochemical disease free survival in intermediate to high-risk patients without impacting toxicity and quality of life.
This focal boost strategy is now proven for a conventional fractionation scheme (35 fractions). The current trend in radiotherapy for prostate cancer is (extreme) hypofractionation, reducing the number of fractions. For locally advanced prostate cancer, however, the data on extreme hypofractionation are scarce.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Male
- Target Recruitment
- 95
- Men aged 18 years or older with histologically proven prostate carcinoma
- Imaging stage T3b (as defined on mpMRI) N0M0
- Intraprostatic lesion visible on MRI
- Capable of giving informed consent
- History of radiotherapy to the pelvis or transurethral resection of the prostate (TURP)
- Contraindications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrophobia
- Absence of pre-treatment PSMA PET CT
- WHO performance score > 2
- International Prostate Symptom Score ≥ 15
- PSA > 30
- Prostate volume >100c
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description MR-guided hypofractionated focal boost radiotherapy Ultrahypofractionated MR-guided radiotherapy boost External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MR
- Primary Outcome Measures
Name Time Method Acute gastrointestinal and genitourinary toxicity 90 days after start of treatment Acute gastrointestinal (GI) and genitourinary (GU) Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Acute toxicity is defined as toxicity occurring within 90 days after the first radiation treatment (e.g. 60 days after completion of the radiation treatment).
- Secondary Outcome Measures
Name Time Method Quality of life from baseline up to 5 years after completion of treatment using the EORTC QLQ-PR25 questionnaires
Late GI and GU toxicity (CTCAE v5.0) from 90 days after start of treatment up to 5 years assessed between 90 days and up to 5 years after the first radiation treatment
Prostate cancer specific survival up to 5 years after completion of treatment Distant metastasis free survival up to 5 years after completion of treatment Biochemical disease free survival up to 5 years after completion of treatment measuring the PSA concentration using the Phoenix definition for biochemical recurrence
Overall survival up to 5 years after completion of treatment
Trial Locations
- Locations (2)
Netherlands Cancer Institute
🇳🇱Amsterdam, Noord Holland, Netherlands
Radboudumc
🇳🇱Nijmegen, Gelderland, Netherlands